Dừng ngay lợi nhuận của bọn tư bản

ấn độ từ chối gia hạn bản quyền cho thuốc chống bệnh lao của Johnson & Johnson,
-----
in many middle-income and poor countries tuberculosis (bệnh lao) remains a major problem. The World Health Organization estimates that about a quarter of all people alive have a latent TB infection (though only a minority develop an active case). In 2021, it killed about 1.6 million people—the second-deadliest disease in the world, behind only COVID-19. Worse, several countries have developed a large number of drug-resistant TB cases, because the bacteria has evolved to counter previous antibiotics.


So it’s great news that the Indian government has shot down an attempt from Johnson & Johnson to extend the patent on the best treatment for drug-resistant TB, which is called bedaquiline. This will enable the production of a generic version of the drug at a greatly reduced cost. It’s not only a benefit for poorer nations with a heavy TB burden, but a lesson the rest of the world can take.

The decision is the result of a challenge filed with the Indian Patent Office by two activists, Nandita Venkatesan and Phumeza Tisle, who are TB survivors from India and South Africa, respectively, with the backing of Médecins Sans Frontières. They argued that Johnson & Johnson’s patent extension argument was spurious, since they didn’t make any real changes to the drug. They just fiddled slightly with the formulation, without a real effect on its mechanism of action.

Tags: healthindia

Post a Comment

Tin liên quan

    Tài chính

    Trung Quốc